Zoetis (FRA:ZOE) Additional Paid-In Capital : €1,092 Mil(As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Zoetis Additional Paid-In Capital?

Zoetis's quarterly additional paid-in capital increased from Sep. 2024 (€1,048 Mil) to Dec. 2024 (€1,129 Mil) but then stayed the same from Dec. 2024 (€1,129 Mil) to Mar. 2025 (€1,092 Mil).

Zoetis's annual additional paid-in capital increased from Dec. 2022 (€1,027 Mil) to Dec. 2023 (€1,039 Mil) and increased from Dec. 2023 (€1,039 Mil) to Dec. 2024 (€1,129 Mil).

Zoetis Additional Paid-In Capital Historical Data

The historical data trend for Zoetis's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zoetis Additional Paid-In Capital Chart

Zoetis Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

875.43

945.18

1,027.07

1,038.96

1,128.81

Zoetis Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															1,035.92	1,064.63	1,047.86	1,128.81	1,091.50

Zoetis Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Zoetis Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Zoetis's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Zoetis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zoetis Inc (FRA:ZOE) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ZTS:USA ZTS:Mexico 1ZTS:Italy 0M3Q:UK ZOE:Germany Z1TS34:Brazil ZOTS:Austria

Address

10 Sylvan Way, Parsippany, NJ, USA, 07054

Website

https://www.zoetis.com

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Zoetis Headlines

No Headlines